Found 12 articles for: "Isotretinoin"
Generative Artificial Intelligence Augmentation of a Clinical Trial of a Dermo-cosmetic Intervention for Acne Remission Maintenance
November 2026 | Volume 25 | Issue 11 | Original Article | 1014 | Copyright © November 2026
Background: A practical application of artificial intelligence (AI) in healthcare is to generate artificial datasets that capture the characteristics of a real source dataset wit...
Read MoreA Narrative Review of Seven Off-Label Treatment Options for Seborrheic Dermatitis
October 2026 | Volume 25 | Issue 10 | Original Article | 943 | Copyright © October 2026
Background: Seborrheic dermatitis (SD) is a chronic inflammatory skin condition driven by overactive sebaceous glands, Malassezia colonization, immune dysfunction, and epidermal ...
Read MoreIsotretinoin Does Not Increase the Risk of Inflammatory Bowel Disease: A TriNetX Retrospective Cohort Analysis
December 2025 | Volume 24 | Issue 12 | Original Article | 1168 | Copyright © December 2025
Background: Background: The increasing use of long-term, low-dose isotretinoin for acne has raised concerns about a potential association with inflammatory bowel disease (IBD), i...
Read MoreConsiderations on Concurrent Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and Isotretinoin
June 2025 | Volume 24 | Issue 6 | Editorials | 638 | Copyright © June 2025
Post-Isotretinoin Acne Management: A Pilot Survey of the American Acne and Rosacea Society Board of Directors
June 2025 | Volume 24 | Issue 6 | Editorials | e38 | Copyright © June 2025
Weight Change and Dose Adjustment in Isotretinoin Therapy: A Retrospective Study
June 2025 | Volume 24 | Issue 6 | Features | 639 | Copyright © June 2025
Isotretinoin is used to treat severe nodulocystic acne. Cumulative doses of 120 to 150 mg/kg have been shown to limit adverse events while maximizing efficacy. Also proven safe, doses of 220 mg/k...
Read MoreConsensus Statements on the Use of Novel Formulations of Isotretinoin: A Modified Delphi Process
June 2024 | Volume 23 | Issue 6 | Original Article | 429 | Copyright © June 2024
Oral isotretinoin remains a mainstay of treatment for severe, recalcitrant nodular acne. Novel formulations of isotretinoin have been developed over the past decade, including lidose isotretinoin...
Read MoreChallenges to Prescribing Isotretinoin to Patients at a Safety Net Hospital Dermatology Clinic
June 2024 | Volume 23 | Issue 6 | Case Reports | 477 | Copyright © June 2024
Self-Reported Long-Term Side Effects of Isotretinoin: A Case Series
April 2023 | Volume 22 | Issue 4 | Features | 423 | Copyright © April 2023
Citation: Ghadimi TR, Martinez MJ, Rieder EA. Self-reported long-term side effects of isotretinoin: A case series. J Drugs Dermatol. 2023;22(4):423-424. doi:10.36849/JDD.2303...
Read MoreOral Vitamin A for Acne Management: A Possible Substitute for Isotretinoin
June 2022 | Volume 21 | Issue 6 | Editorials | 683 | Copyright © June 2022
Background: Recent changes to the iPLEDGE platform left providers without the ability to prescribe isotretinoin to their patients. A potential substitute for isotretinoin could be ben...
Read MoreARTICLE: Advances in Oral Isotretinoin Therapy
May 2021 | Volume 20 | Issue 5 | Supplement Individual Articles | s5 | Copyright © May 2021
Since its approval in 1982, oral isotretinoin has revolutionized acne therapy. However, oral isotretinoin use has long been associated with challenges of variable bioavailability and food dependence. ...
Read MoreFULL SUPPLEMENT: Status Update: Isotretinoin
May 2021 | Volume 20 | Issue 5 | Department | 1s | Copyright © May 2021
© 2026 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.
